Ontology highlight
ABSTRACT:
SUBMITTER: Fury MG
PROVIDER: S-EPMC5398410 | biostudies-other | 2016 Apr
REPOSITORIES: biostudies-other
Fury Matthew G MG Xiao Han H Sherman Eric J EJ Baxi Shrujal S Smith-Marrone Stephanie S Schupak Karen K Gewanter Richard R Gelblum Daphna D Haque Sofia S Schoder Heiko H Shah Jatin P JP Katabi Nora N Kurtzman Rachel R Lipson Brynna B Cox Lisa L Lee Nancy Y NY Pfister David G DG
Head & neck 20150706
<h4>Background</h4>The purpose of this study was to evaluate the efficacy and tolerability of the addition of 2 monoclonal antibodies, bevacizumab and cetuximab, to 2 cycles of high-dose cisplatin administered concurrently with intensity-modulated radiation therapy (IMRT) for head and neck squamous cell carcinoma (HNSCC).<h4>Methods</h4>Patients with newly diagnosed stage III/IVB (M0) HNSCC received cetuximab (400 mg/m(2) loading dose, followed by 250 mg/m(2) weekly), bevacizumab (15 mg/kg, days ...[more]